ClinicalTrials.gg
Not yet recruitingNCT07861113Updated Oct 6, 2026

A Study to Evaluate the Effectiveness and Safety of Sibeprenlimab in Participants With Primary Membranous Nephropathy, Immune-mediated Focal Segmental Glomerulosclerosis, and Minimal Change Disease

A Phase 2 interventional study of Sibeprenlimab in Primary Membranous Nephropathy, Minimal Change Disease and Focal Segmental Glomerulosclerosis, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment

Updated Oct 6, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This study will assess whether sibeprenlimab can help improve kidney disease in adults with primary membranous nephropathy (pMN) by reducing harmful antibodies linked to the disease. The study will also assess whether sibeprenlimab can help adults with immune-mediated focal segmental glomerulosclerosis (IM-FSGS) or minimal change disease (MCD) stay in remission and prevent their kidney disease from returning.

02

Conditions studied

  • Primary Membranous Nephropathy
  • Minimal Change Disease
  • Focal Segmental Glomerulosclerosis

Keywords

  • Primary Membranous Nephropathy
  • Immune-mediated Focal Segmental Glomerulosclerosis
  • Minimal Change Disease
03

In context

Nephrosis, Lipoid

76 studies on the registry are indexed under Nephrosis, Lipoid; 33 are open to participants now.

This study's planned enrollment of 20 is below the median of 49 across 46 interventional studies indexed under Nephrosis, Lipoid.

Browse Nephrosis, Lipoid studies →

Lead sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.

Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For people with pMN:

  1. Be experiencing their first episode of pMN, or have pMN that has returned after getting better (), with ongoing signs of significant kidney disease based on urine and blood tests.
  2. Have a blood test showing high levels of antibodies against PLA2R, a protein linked to pMN, and these antibody levels must not have improved significantly over the previous 8 to 24 weeks.
  3. Be taking a stable, maximum tolerated dose of a kidney-protective medication (such as an angiotensin converting enzyme (ACE) inhibitor or angiotensin II receptor blockers [ARB]) for at least 3 months before screening. Other medications that help reduce protein in the urine may also be allowed if the dose has remained unchanged for at least 3 months.

For people with IM-FSGS or MCD:

  1. Have previously been diagnosed with IM-FSGS or MCD, confirmed by a kidney .
  2. Currently have their disease well controlled, either in complete remission or partial remission, based on urine and blood test results.
  3. Have a disease that depends on treatment (medications that reduce immune system activity), meaning:

    • They need ongoing treatment with medications such as or calcineurin inhibitors (CNIs) to keep the disease under control; and
    • Within the last 18 months, they experienced a return of nephrotic syndrome (severe kidney disease symptoms) shortly after reducing or stopping immunosuppressive treatment.
  4. Be taking a stable dose of steroids or CNIs for at least 4 weeks before screening.

Exclusion criteria

Exclusion Criteria:

  1. Have a kidney condition other than pMN, IM-FSGS or MCD, or have previously received a kidney transplant.
  2. Have another serious disease that could affect their health or study results.
  3. Have a serious active infection, such as (HIV), , , tuberculosis (TB), or other significant chronic infections.
  4. Have uncontrolled high or low blood pressure.
  5. Have a serious medical condition, including certain cancers, that could make study participation unsafe.
  6. Have Type 1 diabetes or poorly controlled Type 2 diabetes.
  7. Have recently received certain immune-suppressing treatments or other medications that could interfere with the study.
  8. Are currently participating in another clinical trial or have recently received an medicine.
  9. Have a history of a severe allergic reaction to ingredients in the study drug.
  10. Have recent alcohol or substance abuse that could interfere with participation.
  11. Are unable to follow study procedures or attend required study visits.

Note: Other protocol-specified Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Sibeprenlimab Subcutaneous Administration

    Participants with primary membranous nephropathy (pMN) and immune-mediated focal segmental glomerulosclerosis (IM-FSGS) or minimal change disease (MCD) will receive a dose every four weeks for a total of seven doses.

    Drug: Sibeprenlimab

Interventions

06

What researchers measure

Primary outcomes

  1. pMN: Percentage of Participants With More Than (>) 80 Percent (%) Reduction From Baseline in Anti-Phospholipase A2 Receptor (PLA2R)

    Time frame: Week 25

  2. IM-FSGS and MCD: Percentage of Participants Remaining in Remission (Complete or Partial Remission) at Week 25

    Complete or partial remission will be determined from the urinary protein/creatinine ratio \[uPCR\] and serum albumin measurements. The criteria for complete remission include uPCR less than \[\<\] 0.3 gram per gram \[g/g\] and normal serum albumin \> 3.5 grams per liter \[g/L\]). Criteria for partial remission include uPCR \< 1.0 g/g and normal serum albumin \> 3.5 g/L.

    Time frame: Week 25

Secondary outcomes

  1. pMN: Change From Baseline in Anti-PLA2R

    Time frame: Baseline, Week 25

  2. pMN, IM-FSGS, and MCD: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs

    Time frame: Up to Week 37

  3. pMN, IM-FSGS, and MCD: Number of Participants With Clinically Significant Change in Laboratory Assessments From Baseline

    Time frame: Baseline, Week 37

  4. pMN, IM-FSGS, and MCD: Number of Participants With Clinically Significant Change in Vital Sign Measurements From Baseline

    Time frame: Baseline, Week 37

  5. pMN, IM-FSGS, and MCD: Number of Participants With Clinically Significant Change in Physical Examination Findings From Baseline

    Time frame: Baseline, Week 37

  6. pMN, IM-FSGS, and MCD: Change From Baseline in Serum Drug Concentration

    Time frame: Baseline, Week 37

  7. pMN, IM-FSGS, and MCD: Change From Baseline in A Proliferation Inducing Ligand (APRIL) Concentrations

    Time frame: Baseline, Week 37

  8. pMN, IM-FSGS, and MCD: Number of Participants With Serum Anti-Drug Antibodies (ADA)

    Time frame: Up to Week 37

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — Anonymized individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.

Access criteria: Otsuka will share data on the Vivli data sharing platform: https://vivli.org/ourmember/Otsuka/

Data sharing details ↗ · clinical-trials.otsuka.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2026; primary completion for Jun 2028, 18 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2026
First posted
Oct 6, 2026
StartEst.
Dec 15, 2026
Primary completionEst.
Jun 15, 2028
CompletionEst.
Sep 15, 2028
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07861113
Responsible party
Sponsor
First posted
Oct 6, 2026
Start date
Dec 15, 2026 (estimated)
Primary completion
Jun 15, 2028 (estimated)
Completion
Sep 15, 2028 (estimated)
Last update
Oct 6, 2026

Study contacts

Otsuka Call Center
Contact
Otsuka-ProfessionalServices@otsuka-us.com
844-687-8522

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sibeprenlimab

Start the discussion